STOK
Stoke Therapeutics Surges Ahead: Q2 Highlights and Future Prospects
Stoke Therapeutics recently concluded its second quarter 2026 business update conference call, offering a comprehensive overview of the company's progress across various fronts. Key highlights from the presentation include the ongoing phase III EMPEROR study, which is making steady strides towards a data readout in Q3 2027. The